Athira Pharma Inc. (ATHA)
| Bid | 0.4 |
| Market Cap | 15.42M |
| Revenue (ttm) | 1.66M |
| Net Income (ttm) | -109.65M |
| EPS (ttm) | -2.52 |
| PE Ratio (ttm) | -0.16 |
| Forward PE | -0.32 |
| Analyst | Hold |
| Ask | 0.42 |
| Volume | 28,593 |
| Avg. Volume (20D) | 249,624 |
| Open | 0.41 |
| Previous Close | 0.41 |
| Day's Range | 0.40 - 0.43 |
| 52-Week Range | 0.37 - 4.21 |
| Beta | 2.98 |
About ATHA
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkins...
Analyst Forecast
According to 4 analyst ratings, the average rating for ATHA stock is "Hold." The 12-month stock price forecast is $11.25, which is an increase of 2748.10% from the latest price.
2 months ago · proactiveinvestors.com
ATHA Energy identifies high-grade uranium mineralization in new outcrops at AngilakATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) said it has uncovered numerous outcrops hosting high-grade uranium mineralization at Angilak in Nunavut. The surficial mapping program, centered around the L...